KNTPF (Kintor Pharmaceutical) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kintor Pharmaceutical's EBITDA for the six months ended in Dec. 2023 was $-118.78 Mil. Kintor Pharmaceutical's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Kintor Pharmaceutical's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

Kintor Pharmaceutical EBITDA Margin % Historical Data

The historical data trend for Kintor Pharmaceutical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical EBITDA Margin % Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-2,422.22

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBITDA Margin %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Kintor Pharmaceutical's EBITDA Margin %

For the Biotechnology subindustry, Kintor Pharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintor Pharmaceutical's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's EBITDA Margin % falls into.

Kintor Pharmaceutical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kintor Pharmaceutical's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-145.681	/	0
	=	%

Kintor Pharmaceutical's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-118.778	/	0
	=	%

Kintor Pharmaceutical (OTCPK:KNTPF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Kintor Pharmaceutical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

09939:Hong Kong

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.